Dynamic interaction between fluconazole and amphotericin B against Cryptococcus gattii

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 5, 2012, Pages 2553-2558

  Santos, Julliana Ribeiro Alves ^a   Gouveia, Ludmila Ferreira ^a   Taylor, Erika Linzi Silva ^a   Resende Stoianoff, Maria Aparecida ^a   Pianetti, Gerson Antônio ^a   César, Isabela Costa ^a   Santos, Daniel Assis ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ERGOSTEROL; FLUCONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CORRELATION ANALYSIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; DRUG ACTIVITY; DRUG CONCENTRATION; FRACTIONAL INHIBITORY CONCENTRATION; FUNGAL STRAIN; FUNGAL VIABILITY; IC 50; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CELL MEMBRANE; CRYPTOCOCCUS GATTII; CULTURE MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ANTAGONISM; DRUG SYNERGISM; ERGOSTEROL; FLUCONAZOLE; HUMANS; MICROBIAL SENSITIVITY TESTS; SPECIES SPECIFICITY; SPECTROPHOTOMETRY;

EID: 84860130517     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.06098-11     Document Type: Article

References (27)

1. Arthington-Skaggs BA, Jradi H, Desai T, Morrison CJ. 1999. Quantification of ergosterol content: novel method for determination of fluconazole susceptibility of Candida albicans. J. Clin. Microbiol. 37:3332-3337. (Pubitemid 29455229)
2. Barchiesi F, et al. 2000. Interactions between triazoles and amphotericin B against Cryptococcus neoformans. Antimicrob. Agents Chemother. 44: 2435-2441. (Pubitemid 30650892)
3. Byrnes EJ, III, Bartlett KH, Perfect JR, Heitman J. 2011. Cryptococcus gattii: an emerging fungal pathogen infecting humans and animals. Microbes Infect. 13:1-13.
4. Casalinuovo IA, Di Francesco P, Garaci E. 2004. Fluconazole resistance in Candida albicans: a review of mechanism. Eur. Rev. Med. Pharmacol. Sci. 8:69-77. (Pubitemid 38961746)
5. Chen A, Playford SC, Sorrell TC. 2010. Antifungal therapy in invasive fungal infections. Curr. Opin. Pharmacol. 10:522-530.
6. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A3, 3rd ed. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Corrêa MPSC, et al. 1999. Cryptococcosis in children in the State of Pará, Brazil. Rev. Soc. Bras. Med. Trop. 32:505-508.
8. Cuenca-Estrella M, et al. 2005. Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus. Antimicrob. Agents Chemother. 49: 1232-1235. (Pubitemid 40327758)
9. Ernst EJ, Klepser ME, Pfaller MA. 2000. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob. Agents Chemother. 44:1108-1111. (Pubitemid 30165304)
10. Fica AC. 2004. Treatment of systemic fungal infections. I. Fluconazole, itraconazole, and voriconazole. Rev. Chilena Infectol. 21:26-38.
11. García MT, Llorente MT, Mínguez F, Prieto J. 2002. Post-antifungal effect and effects of sub-MIC concentrations on previously treated Candida spp. influence of growth phase. J. Infect. 45:263-267. (Pubitemid 36104860)
12. Gómez-López A, Cuenca-Estrella M, Mellado E, Rodriguez-Tudella JL. 2003. In vitro evaluation of combination of terbinafine with itraconazole or amphotericin B against Zygomycota. Diagn. Microbiol. Infect. Dis. 45: 199-202. (Pubitemid 36349660)
13. Johnson MD, MacDougall C, Ostrosky-Zeichner L, Perfect JR, Rex JH. 2004. Combination antifungal therapy. Antimicrob. Agents Chemother. 48:693-715. (Pubitemid 38280314)
14. Klepser ME, Wolfe EJ, Jones RN, Nightingale CH, Pfaller MA. 1997. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans. Antimicrob. Agents Chemother. 41:1392-1395. (Pubitemid 27231450)
15. Kontoyiannis DP, et al. 2000. Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: an Etest-based strategy. Antimicrob. Agents Chemother. 44:2915-2918.
16. Kontoyiannis DP, Lewis RE. 2003. Combination chemotherapy for invasive fungal infections: what laboratory and clinical studies tell us thus far. Drug Resist. Update 6:257-269. (Pubitemid 37493782)
17. Kratzer C, Tobudic S, Schmoll M, Graninger W, Georgopoulos A. 2006. In vitro activity and synergism of amphotericin B, azoles, and cationic antimicrobials against the emerging pathogen Trichoderma spp. J. Antimicrob. Chemother. 58:1058-1061.
18. Meletiadis J, Stergiopoulou T, O'Shaughnessy EM, Peter J, Walsh TJ. 2007. Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model. Antimicrob. Agents Chemother. 51:2053-2064. (Pubitemid 46903094)
19. Mendes FES, et al. 2010. Correlation of the in vitro antifungal drug susceptibility with the in vivo activity of fluconazole in a murine model of cerebral infection caused by Cryptococcus gattii. Eur. J. Clin. Microbiol. Infect. Dis. doi:10.1007/s10096-010-1034-8.
20. Mukherjee PK, Sheehan DJ, Hitchcock CA, Ghannoum MA. 2005. Combination treatment of invasive fungal infections. Clin. Microbiol. Rev. 18:163-194. (Pubitemid 40170667)
21. Nooney L, Matthews RC, Burnie JP. 2005. Evaluation of Mycograb, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and time-kill methodologies. Diagn. Microbiol. Infect. Dis. 51:19-29. (Pubitemid 40040564)
22. Odds FC. 2003. Synergy, antagonism, and what the checkerboard puts between them. J. Antimicrob. Chemother. 52:1. (Pubitemid 36850074)
23. O'Shaughnessy EM, Meletiadis J, Stergiopoulou TT, Demchok JP, Walsh TJ. 2006. Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species. J. Antimicrob. Chemother. 58:1168-1176. (Pubitemid 44884135)
24. Revankar SG, et al. 2004. Cloning and characterization of the lanosterol 14 α-demethylase (ERG11) gene in Cryptococcus neoformans. Biochem. Biophys. Res. Commun. 324:719-728. (Pubitemid 39345576)
25. Santos DA, Barros MES, Hamdan JS. 2006. Establishing a method of inoculum preparation for susceptibility testing of Trichophyton rubrum and Trichophyton mentagrophytes. J. Clin. Microbiol. 44:98-101. (Pubitemid 43100586)
26. Soares BM, et al. 2008. Cerebral infection caused by Cryptococcus gattii: a case report and antifungal susceptibility testing. Rev. Iberoam. Micol. 25: 242-245.
27. Soares BM, et al. 2011. Cryptococcus gattii: in vitro susceptibility to photodynamic inactivation. Photochem. Photobiol. 87:357-364.